Last reviewed · How we verify
Placebo to match sitagliptin
This is an inert placebo formulation designed to match the appearance and administration of sitagliptin for use in blinded clinical trials.
This is an inert placebo formulation designed to match the appearance and administration of sitagliptin for use in blinded clinical trials. Used for Control comparator in clinical trials evaluating sitagliptin efficacy.
At a glance
| Generic name | Placebo to match sitagliptin |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo products contain no active pharmaceutical ingredient and are used as control comparators in randomized controlled trials to assess the efficacy of the active drug through blinded comparison. This specific placebo is manufactured to match sitagliptin tablets in appearance, size, and packaging to maintain trial blinding and reduce bias.
Approved indications
- Control comparator in clinical trials evaluating sitagliptin efficacy
Common side effects
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers (PHASE1)
- Cardiovascular Effects of GLP-1 Receptor Activation (PHASE4)
- Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients (PHASE3)
- Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) (PHASE3)
- Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure (PHASE4)
- Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (PHASE3)
- A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match sitagliptin CI brief — competitive landscape report
- Placebo to match sitagliptin updates RSS · CI watch RSS
- AstraZeneca portfolio CI